ホーム > 市場調査レポート > 医薬品

バイオ医薬品分子標的療法

市場調査レポート

商品コード

1422081

モノクローナル抗体の世界市場：生産方法別、適応症別、由来別、投与経路別、流通チャネル別、エンドユーザー別、地域別、機会、予測、2017年～2031年

Monoclonal Antibodies Market Assessment, By Production Methods, By Indication, By Source, By Route of Administration, By Distribution Channel, By End-users, By Region, Opportunities and Forecast, 2017-2031F

出版日: 2024年02月07日
発行: Markets & Data
ページ情報: 英文 232 Pages
納期: 3～5営業日

カスタマイズ可能

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界のモノクローナル抗体の市場規模は、2023年に2,164億米ドルと評価され、2031年には5,548億4,000万米ドルに達すると予測されており、2024年から2031年の予測期間のCAGRは12.49%になるとみられています。世界のモノクローナル抗体市場の拡大は、バイオテクノロジー研究の活発化、慢性疾患の蔓延、技術の進歩、幅広い治療への応用、個別化医療への要望の高まりに起因しています。さらに、新規モノクローナル抗体ベースの治療法の承認と有効性は、世界のモノクローナル抗体市場の成長を促進する上で重要な役割を果たしています。

世界のモノクローナル抗体市場の大幅な成長は、主に様々な極めて重要な要素に由来します。まず、バイオテクノロジー研究への重点化と投資の増加が、顕著に上昇傾向に拍車をかけています。研究環境の拡大は、モノクローナル抗体に基づく画期的な治療法の創出を育み、新たな治療アプローチへの道を開きました。さらに、慢性疾患の世界の増加により、正確で効果的な治療が必要とされています。モノクローナル抗体は、疾患の原因物質を標的にする精度の高さで知られており、多様な慢性疾患を管理するための有望なソリューションとして浮上してきました。さらに、モノクローナル抗体の世界市場では、生産プロセスを改良し、モノクローナル抗体治療へのアクセス性と有効性を高めることで、技術の進歩が重要な役割を果たしています。

モノクローナル抗体の非伝統的な医療領域への使用拡大が、世界のモノクローナル抗体市場の拡大をさらに後押ししています。モノクローナル抗体の用途は現在、腫瘍学、自己免疫疾患、感染症など様々な分野に広がっており、幅広い健康問題に対処する上でその関連性が高まっています。世界のモノクローナル抗体市場は、個別化医療に対する需要の高まりの影響を受けており、個々の疾患反応に対するより深い理解がモノクローナル抗体の採用を加速させています。モノクローナル抗体の特定の分子標的への適応性は、個別化ヘルスケアのアプローチにシームレスに合致し、現代医療におけるその重要性を強調しています。さらに、新しいモノクローナル抗体療法が支持され、その有効性が証明されることで、市場での地位が強化され、ヘルスケアプロバイダーや患者にも大きな信頼を与えることになります。このことは、世界のモノクローナル抗体市場の継続的な拡大を推進する上で、極めて重要な役割を担っていることを裏付けています。

当レポートでは、世界のモノクローナル抗体市場について調査し、市場の概要とともに、生産方法別、適応症別、由来別、投与経路別、流通チャネル別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

List of Tables

Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1. Global Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
Figure 2. Global Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
Figure 3. Global Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
Figure 4. Global Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
Figure 5. Global Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
Figure 6. Global Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
Figure 7. Global Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
Figure 8. Global Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
Figure 9. Global Monoclonal Antibodies Market Share (%), By Region, 2017-2031F
Figure 10. North America Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
Figure 11. North America Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
Figure 12. North America Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
Figure 13. North America Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
Figure 14. North America Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
Figure 15. North America Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
Figure 16. North America Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
Figure 17. North America Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
Figure 18. North America Monoclonal Antibodies Market Share (%), By Country, 2017-2031F
Figure 19. United States Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
Figure 20. United States Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
Figure 21. United States Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
Figure 22. United States Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
Figure 23. United States Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
Figure 24. United States Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
Figure 25. United States Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
Figure 26. United States Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
Figure 27. Canada Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
Figure 28. Canada Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
Figure 29. Canada Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
Figure 30. Canada Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
Figure 31. Canada Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
Figure 32. Canada Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
Figure 33. Canada Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
Figure 34. Canada Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
Figure 35. Mexico Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
Figure 36. Mexico Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
Figure 37. Mexico Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
Figure 38. Mexico Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
Figure 39. Mexico Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
Figure 40. Mexico Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
Figure 41. Mexico Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
Figure 42. Mexico Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
Figure 43. Europe Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
Figure 44. Europe Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
Figure 45. Europe Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
Figure 46. Europe Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
Figure 47. Europe Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
Figure 48. Europe Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
Figure 49. Europe Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
Figure 50. Europe Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
Figure 51. Europe Monoclonal Antibodies Market Share (%), By Country, 2017-2031F
Figure 52. Germany Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
Figure 53. Germany Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
Figure 54. Germany Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
Figure 55. Germany Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
Figure 56. Germany Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
Figure 57. Germany Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
Figure 58. Germany Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
Figure 59. Germany Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
Figure 60. France Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
Figure 61. France Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
Figure 62. France Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
Figure 63. France Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
Figure 64. France Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
Figure 65. France Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
Figure 66. France Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
Figure 67. France Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
Figure 68. Italy Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
Figure 69. Italy Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
Figure 70. Italy Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
Figure 71. Italy Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
Figure 72. Italy Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
Figure 73. Italy Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
Figure 74. Italy Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
Figure 75. Italy Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
Figure 76. United Kingdom Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
Figure 77. United Kingdom Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
Figure 78. United Kingdom Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
Figure 79. United Kingdom Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
Figure 80. United Kingdom Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
Figure 81. United Kingdom Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
Figure 82. United Kingdom Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
Figure 83. United Kingdom Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
Figure 84. Russia Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
Figure 85. Russia Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
Figure 86. Russia Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
Figure 87. Russia Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
Figure 88. Russia Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
Figure 89. Russia Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
Figure 90. Russia Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
Figure 91.
Figure 92. Russia Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
Figure 93. Netherlands Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
Figure 94. Netherlands Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
Figure 95. Netherlands Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
Figure 96. Netherlands Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
Figure 97. Netherlands Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
Figure 98. Netherlands Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
Figure 99. Netherlands Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
Figure 100. Netherlands Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
Figure 101. Spain Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
Figure 102. Spain Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
Figure 103. Spain Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
Figure 104. Spain Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
Figure 105. Spain Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
Figure 106. Spain Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
Figure 107. Spain Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
Figure 108. Spain Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
Figure 109. Turkey Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
Figure 110. Turkey Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
Figure 111. Turkey Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
Figure 112. Turkey Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
Figure 113. Turkey Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
Figure 114. Turkey Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
Figure 115. Turkey Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
Figure 116. Turkey Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
Figure 117. Poland Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
Figure 118. Poland Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
Figure 119. Poland Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
Figure 120. Poland Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
Figure 121. Poland Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
Figure 122. Poland Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
Figure 123. Poland Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
Figure 124. Poland Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
Figure 125. South America Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
Figure 126. South America Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
Figure 127. South America Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
Figure 128. South America Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
Figure 129. South America Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
Figure 130. South America Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
Figure 131. South America Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
Figure 132. South America Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
Figure 133. South America Monoclonal Antibodies Market Share (%), By Country, 2017-2031F
Figure 134. Brazil Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
Figure 135. Brazil Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
Figure 136. Brazil Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
Figure 137. Brazil Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
Figure 138. Brazil Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
Figure 139. Brazil Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
Figure 140. Brazil Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
Figure 141. Brazil Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
Figure 142. Argentina Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
Figure 143. Argentina Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
Figure 144. Argentina Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
Figure 145. Argentina Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
Figure 146. Argentina Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
Figure 147. Argentina Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
Figure 148. Argentina Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
Figure 149. Argentina Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
Figure 150. Asia-Pacific Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
Figure 151. Asia-Pacific Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
Figure 152. Asia-Pacific Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
Figure 153. Asia-Pacific Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
Figure 154. Asia-Pacific Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
Figure 155. Asia-Pacific Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
Figure 156. Asia-Pacific Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
Figure 157. Asia-Pacific Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
Figure 158. Asia-Pacific Monoclonal Antibodies Market Share (%), By Country, 2017-2031F
Figure 159. India Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
Figure 160. India Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
Figure 161. India Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
Figure 162. India Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
Figure 163. India Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
Figure 164. India Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
Figure 165. India Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
Figure 166. India Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
Figure 167. China Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
Figure 168. China Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
Figure 169. China Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
Figure 170. China Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
Figure 171. China Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
Figure 172. China Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
Figure 173. China Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
Figure 174. China Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
Figure 175. Japan Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
Figure 176. Japan Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
Figure 177. Japan Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
Figure 178. Japan Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
Figure 179. Japan Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
Figure 180. Japan Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
Figure 181. Japan Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
Figure 182. Japan Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
Figure 183. Australia Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
Figure 184. Australia Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
Figure 185. Australia Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
Figure 186. Australia Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
Figure 187. Australia Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
Figure 188. Australia Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
Figure 189. Australia Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
Figure 190. Australia Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
Figure 191. Vietnam Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
Figure 192. Vietnam Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
Figure 193. Vietnam Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
Figure 194. Vietnam Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
Figure 195. Vietnam Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
Figure 196. Vietnam Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
Figure 197. Vietnam Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
Figure 198. Vietnam Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
Figure 199. South Korea Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
Figure 200. South Korea Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
Figure 201. South Korea Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
Figure 202. South Korea Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
Figure 203. South Korea Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
Figure 204. South Korea Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
Figure 205. South Korea Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
Figure 206. South Korea Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
Figure 207. Indonesia Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
Figure 208. Indonesia Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
Figure 209. Indonesia Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
Figure 210. Indonesia Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
Figure 211. Indonesia Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
Figure 212. Indonesia Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
Figure 213. Indonesia Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
Figure 214. Indonesia Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
Figure 215. Philippines Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
Figure 216. Philippines Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
Figure 217. Philippines Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
Figure 218. Philippines Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
Figure 219. Philippines Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
Figure 220. Philippines Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
Figure 221. Philippines Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
Figure 222. Philippines Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
Figure 223. Middle East & Africa Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
Figure 224. Middle East & Africa Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
Figure 225. Middle East & Africa Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
Figure 226. Middle East & Africa Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
Figure 227. Middle East & Africa Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
Figure 228. Middle East & Africa Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
Figure 229. Middle East & Africa Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
Figure 230. Middle East & Africa Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
Figure 231. Middle East & Africa Monoclonal Antibodies Market Share (%), By Country, 2017-2031F
Figure 232. Saudi Arabia Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
Figure 233. Saudi Arabia Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
Figure 234. Saudi Arabia Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
Figure 235. Saudi Arabia Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
Figure 236. Saudi Arabia Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
Figure 237. Saudi Arabia Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
Figure 238. Saudi Arabia Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
Figure 239. Saudi Arabia Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
Figure 240. UAE Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
Figure 241. UAE Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
Figure 242. UAE Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
Figure 243. UAE Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
Figure 244. UAE Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
Figure 245. UAE Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
Figure 246. UAE Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
Figure 247. UAE Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
Figure 248. South Africa Monoclonal Antibodies Market, By Value, In USD Billion, 2017-2031F
Figure 249. South Africa Monoclonal Antibodies Market, By Volume, In Millions, 2017-2031F
Figure 250. South Africa Monoclonal Antibodies Market Share (%), By Production Methods, 2017-2031F
Figure 251. South Africa Monoclonal Antibodies Market Share (%), By Indication, 2017-2031F
Figure 252. South Africa Monoclonal Antibodies Market Share (%), By Source, 2017-2031F
Figure 253. South Africa Monoclonal Antibodies Market Share (%), By Route of Administration, 2017-2031F
Figure 254. South Africa Monoclonal Antibodies Market Share (%), By Distribution Channel, 2017-2031F
Figure 255. South Africa Monoclonal Antibodies Market Share (%), By End-users, 2017-2031F
Figure 256. By Production Methods Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 257. By Indication Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 258. By Source Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 259. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 260. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 261. By End-users Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 262. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Product Code: MX10946

Global monoclonal antibodies market size was valued at USD 216.4 billion in 2023, which is expected to reach USD 554.84 billion in 2031, with a CAGR of 12.49% for the forecast period between 2024 and 2031F. The expansion of the global monoclonal antibodies market stems from augmented biotechnology research, escalating chronic disease prevalence, advancements in technology, broader therapeutic applications, and an increasing desire for personalized medicine. Moreover, the approval and efficacy of novel monoclonal antibody-based therapies play a substantial role in driving the growth of the global monoclonal antibodies market.

The substantial growth of the global monoclonal antibodies market derives primarily from various pivotal elements. Initially, the increasing emphasis and investment in biotechnology research have notably fueled an upward trend. The expanded research environment has nurtured the creation of groundbreaking therapies based on monoclonal antibodies, opening pathways for fresh treatment approaches. Moreover, the increasing worldwide incidence of chronic diseases necessitates precise and effective treatments. Monoclonal antibodies, known for their precision in targeting disease agents, have emerged as promising solutions for managing diverse chronic conditions. Additionally, technological advancements have played a crucial role by refining production processes and augmenting the accessibility and effectiveness of monoclonal antibody treatments in the global monoclonal antibodies market.

Expanding use of monoclonal antibodies into non-traditional medical domains has further propelled expansion of the global monoclonal antibodies market. Their application now spans across various fields such as oncology, autoimmune disorders, infectious diseases, and more, amplifying their relevance in addressing a broad spectrum of health concerns. The global monoclonal antibodies market is influenced by the rising demand for personalized medicine, fueled by a deeper comprehension of individual disease responses, accelerating the adoption of monoclonal antibodies. Their adaptability to specific molecular targets aligns seamlessly with the personalized healthcare approach, underscoring their significance in modern medical practices. Furthermore, the endorsement and proven effectiveness of new monoclonal antibody therapies reinforce their market standing, instilling greater confidence among healthcare providers and patients alike. It solidifies their pivotal role in continually propelling the ongoing expansion of the global monoclonal antibodies market.

Escalating Chronic Disease Prevalence

The growing prevalence of chronic illnesses acts as a major driver fuelling the expansion of global monoclonal antibodies market. Roughly one in three persons worldwide deal with several chronic illnesses. In the United States, four out of ten persons have two or more chronic diseases, and six out of ten adults have one or more. With chronic conditions impacting a larger population worldwide, there is an increased demand for precise and efficient therapeutic remedies.

Monoclonal antibodies are commended for accurately pinpointing specific disease-causing elements that have become fundamental in managing various chronic health issues. Their capability to precisely identify and counteract these elements position them as a promising avenue for addressing ailments such as cancer, autoimmune disorders, and persistent infections. As complexities of the molecular intricacies behind chronic diseases advance, monoclonal antibodies provide customized treatments, addressing the intricacies of individual patient responses. This synchronization between the requirement for accurate, targeted treatments and the adaptability of monoclonal antibodies significantly elevates their importance in tackling the surge of chronic diseases, thereby fostering the growth of the global monoclonal antibodies market.

Technological Advancements

Advances in technology within monoclonal antibody development and manufacturing have transformed the global monoclonal antibodies market. Various platforms have arisen, refining manufacturing procedures and boosting effectiveness. Breakthroughs such as recombinant DNA technology and high-throughput screening accelerated antibody discovery and production. Moreover, enhancements in bioreactor design and purification methods optimize production, guaranteeing increased yields and purity levels. These technological leaps accelerate antibody development and enhance cost-efficiency and scalability, satisfying the rising need for these treatments. Thus, these advancements significantly drive the rapid expansion of the global monoclonal antibodies market., SUREmAb is an offering launched in September 2023 by JSR Life Sciences Company KPI Biopharma, Inc., based on the KBI SUREtechnology platform and intended to optimise and economically manufacture monoclonal antibodies (mAbs). It is intended to shorten the time needed for development. Furthermore, SUREmAb is designed to deliver titers of up to 10g/L using a less expensive approach to maximise ROI and optimise operational efficiency.

Government Initiatives

Around the globe, governments are proactively executing diverse initiatives to encourage global monoclonal antibodies market growth. These efforts involve a range of approaches: funding research and development, providing incentives for biotech firms, optimizing regulatory procedures to expedite approvals, and fostering partnerships between academia and industry. Moreover, certain government aid in infrastructure improvements is expected to fortify manufacturing capacities and ensure effective distribution channels. These coordinated governmental actions underscore their acknowledgment of monoclonal antibodies' significance in healthcare, aiming to stimulate advancements, affordability, accessibility, and broader market expansion. As part of Project NextGen, which aims to improve readiness for COVID-19 strains and variants, the U.S. Department of Health, and Human Services (HHS) announced the extension of its public-private partnership with Regeneron Pharmaceuticals, Inc., an American biotechnology company, to develop life-saving monoclonal antibodies in September 2023. The HHS is dedicated to cutting down prescription expenses for every American. In the agreement, Regeneron promised that any new product commercialized in the list price within the United States would match or be lower than the retail price compared to the global markets.

Monoclonal Antibodies for Cancer Treatment

Monoclonal antibodies are integral in cancer treatment, serving as a significant driver for the growth of the global monoclonal antibodies market. Their precision targets cancer cells while preserving healthy ones and reducing adverse effects compared to conventional treatments. Operating through mechanisms like inhibiting cell growth or marking cells for immune elimination, these antibodies demonstrate their effectiveness in approved therapies like trastuzumab in breast cancer or rituximab in lymphoma. Ongoing research exploration synergizes them with other treatments for amplified results. Their triumph in cancer therapy escalates demand, fueling ongoing market growth and presenting hopeful avenues for more precise and potent cancer management.

Manaolana Oncology Inc., a new firm founded to explore and promote antibody-based therapeutics against novel cancer antigens, was unveiled in September 2023 by Panacea Venture and The University of Texas MD Anderson Cancer Centre. To advance promising treatments into clinical trials at MD Anderson, Manaolana Oncology aims to expand on the inventive antibody production capabilities and intellectual property of MD Anderson by conducting research and developing novel monoclonal antibodies (mAbs) and other antibody-based therapies for a range of cancer types.

Dominance of Chimeric Monoclonal Antibody

The global monoclonal antibodies market sees a substantial demand for chimeric antibodies owing to their distinct blend of human and non-human antibody components. The hybrid makeup amplifies their therapeutic value by lessening immune responses and enhancing effectiveness. Widely applied in cancer and autoimmune disorder treatments, these antibodies demonstrate minimal side effects and heightened precision in targeting. The market's keen interest in these antibodies arises from their capacity to deliver superior treatment results, mitigate adverse effects, and elevate patient tolerance.

Consequently, their remarkable demand and prominence persist in the global monoclonal antibodies sector. Enzene Biosciences released Cetuximab, a biosimilar of the cancer medication Erbitux, in May 2023. A single patient's eight weeks of treatment with cetuximab, a therapeutic chimeric monoclonal antibody, costs over USD 30 thousand. It is used as a targeted therapy for metastatic colorectal cancer (mCRC) and cancer of the head and neck. Cetuximab from Enzene is made using Chinese Hamster Ovary (CHO) cell lines, which produce more human-like glycosylation patterns. As a result, unfavourable effects in clinical trials are much less common in India.

Future Market Scenario

The future of the global monoclonal antibodies market holds considerable promise, attributed to diverse factors. Ongoing research continuously unveils fresh antibody therapies, extending their applications beyond current boundaries. Technological advancements, such as refined manufacturing approaches and inventive antibody designs, drive cost-effectiveness and bolster therapeutic efficiency. Moreover, the rising worldwide prevalence of chronic ailments perpetuates the demand for precise, personalized treatments, an area where monoclonal antibodies demonstrate significant potential. Government support through funding and streamlined regulations further accelerates market growth. Additionally, the market's adoption of advanced antibody structures, including chimeric varieties, underscores the persistent pursuit of improved patient outcomes. The combination of factors establishes a platform for substantial growth in the global monoclonal antibodies market, promising enhanced innovation, expanded applications, increased accessibility, and heightened effectiveness in managing diverse health conditions.

Key Players Landscape and Outlook

Multiple companies in global monoclonal antibodies market are actively seeking collaborative alliances. These partnerships facilitate the consolidation of knowledge, resources, and technologies, fostering innovation and expediting research and development endeavors. Often, these collaborations entail biotech entities partnering with pharmaceutical leaders, academia, or research bodies to leverage combined strengths in discovering new therapies or refining the current ones.

Through joint ventures, licensing pacts, and research collaborations, there is a mutual exchange of expertise and capabilities, aiming to bolster product pipelines, hasten regulatory approvals, and broaden market presence. The concerted effort ensures a more robust competitive advantage amid the dynamic realm of monoclonal antibody therapies.

A biotech business Icosagen and the Swedish company Salipro Biotech signed a multi-target antibody research partnership in October 2023. According to a statement released on October 10, the agreement made use of Salipro's exclusive platform technology for membrane proteins to find medications that specifically target G protein-coupled receptors (GPCRs) and solute carrier (SLC) transporters. These membrane proteins are involved in autoimmune disorders and cancer, among other things.

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Monoclonal Antibodies Market Outlook, 2017-2031F

4.1. Market Size & Forecast
- 4.1.1. Value
- 4.1.2. Volume
4.2. By Production Methods
- 4.2.1. In Vivo
- 4.2.2. In Vitro
4.3. By Indication
- 4.3.1. Disease Treatment
  - 4.3.1.1. Cancer
  - 4.3.1.2. Organ Transplant Rejection
  - 4.3.1.3. Inflammatory and Autoimmune Disorders
  - 4.3.1.4. Infections
  - 4.3.1.5. Osteoporosis
  - 4.3.1.6. Others
- 4.3.2. Diagnosis
- 4.3.3. Research
4.4. By Source
- 4.4.1. Chimeric
- 4.4.2. Human
- 4.4.3. Murine
- 4.4.4. Humanized
- 4.4.5. Others
4.5. By Route of Administration
- 4.5.1. Oral
- 4.5.2. Intravenous
- 4.5.3. Subcutaneous
- 4.5.4. Intramuscular
- 4.5.5. Intravitreal
- 4.5.6. Others
4.6. By Distribution Channel
- 4.6.1. Hospital Pharmacy
- 4.6.2. Retail Pharmacy
- 4.6.3. Online Pharmacy
- 4.6.4. Others
4.7. By End-users
- 4.7.1. Hospitals
- 4.7.2. Specialty Clinics
- 4.7.3. Homecare
- 4.7.4. Others
4.8. By Region
- 4.8.1. North America
- 4.8.2. Europe
- 4.8.3. South America
- 4.8.4. Asia-Pacific
- 4.8.5. Middle East and Africa
4.9. By Company Market Share (%), 2023

5. Global Monoclonal Antibodies Market Outlook, By Region, 2017-2031F

5.1. North America*
- 5.1.1. Market Size & Forecast
  - 5.1.1.1. Value
  - 5.1.1.2. Volume
- 5.1.2. By Production Methods
  - 5.1.2.1. In Vivo
  - 5.1.2.2. In Vitro
- 5.1.3. By Indication
  - 5.1.3.1. Disease Treatment
  - 5.1.3.1.1. Cancer
  - 5.1.3.1.2. Organ Transplant Rejection
  - 5.1.3.1.3. Inflammatory and Autoimmune Disorders
  - 5.1.3.1.4. Infections
  - 5.1.3.1.5. Osteoporosis
  - 5.1.3.1.6. Others
  - 5.1.3.2. Diagnosis
  - 5.1.3.3. Research
- 5.1.4. By Source
  - 5.1.4.1. Chimeric
  - 5.1.4.2. Human
  - 5.1.4.3. Murine
  - 5.1.4.4. Humanized
  - 5.1.4.5. Others
- 5.1.5. By Route of Administration
  - 5.1.5.1. Oral
  - 5.1.5.2. Intravenous
  - 5.1.5.3. Subcutaneous
  - 5.1.5.4. Intramuscular
  - 5.1.5.5. Intravitreal
  - 5.1.5.6. Others
- 5.1.6. By Distribution Channel
  - 5.1.6.1. Hospital Pharmacy
  - 5.1.6.2. Retail Pharmacy
  - 5.1.6.3. Online Pharmacy
  - 5.1.6.4. Others
- 5.1.7. By End-users
  - 5.1.7.1. Hospitals
  - 5.1.7.2. Specialty Clinics
  - 5.1.7.3. Homecare
  - 5.1.7.4. Others
- 5.1.8. United States*
  - 5.1.8.1. By Production Methods
  - 5.1.8.1.1. In Vivo
  - 5.1.8.1.2. In Vitro
  - 5.1.8.2. By Indication
  - 5.1.8.2.1. Disease Treatment
  - 5.1.8.2.1.1. Cancer
  - 5.1.8.2.1.2. Organ Transplant Rejection
  - 5.1.8.2.1.3. Inflammatory and Autoimmune Disorders
  - 5.1.8.2.1.4. Infections
  - 5.1.8.2.1.5. Osteoporosis
  - 5.1.8.2.1.6. Others
  - 5.1.8.2.2. Diagnosis
  - 5.1.8.2.3. Research
  - 5.1.8.3. By Source
  - 5.1.8.3.1. Chimeric
  - 5.1.8.3.2. Human
  - 5.1.8.3.3. Murine
  - 5.1.8.3.4. Humanized
  - 5.1.8.3.5. Others
  - 5.1.8.4. By Route of Administration
  - 5.1.8.4.1. Oral
  - 5.1.8.4.2. Intravenous
  - 5.1.8.4.3. Subcutaneous
  - 5.1.8.4.4. Intramuscular
  - 5.1.8.4.5. Intravitreal
  - 5.1.8.4.6. Others
  - 5.1.8.5. By Distribution Channel
  - 5.1.8.5.1. Hospital Pharmacy
  - 5.1.8.5.2. Retail Pharmacy
  - 5.1.8.5.3. Online Pharmacy
  - 5.1.8.5.4. Others
  - 5.1.8.6. By End-users
  - 5.1.8.6.1. Hospitals
  - 5.1.8.6.2. Specialty Clinics
  - 5.1.8.6.3. Homecare
  - 5.1.8.6.4. Others
- 5.1.9. Canada
- 5.1.10. Mexico

All segments will be provided for all regions and countries covered:

5.2. Europe
- 5.2.1. Germany
- 5.2.2. France
- 5.2.3. Italy
- 5.2.4. United Kingdom
- 5.2.5. Russia
- 5.2.6. Netherlands
- 5.2.7. Spain
- 5.2.8. Turkey
- 5.2.9. Poland
5.3. South America
- 5.3.1. Brazil
- 5.3.2. Argentina
5.4. Asia-Pacific
- 5.4.1. India
- 5.4.2. China
- 5.4.3. Japan
- 5.4.4. Australia
- 5.4.5. Vietnam
- 5.4.6. South Korea
- 5.4.7. Indonesia
- 5.4.8. Philippines
5.5. Middle East & Africa
- 5.5.1. Saudi Arabia
- 5.5.2. UAE
- 5.5.3. South Africa

6. Market Mapping, 2023

6.1. By Production Methods
6.2. By Indication
6.3. By Source
6.4. By Route of Administration
6.5. By Distribution Channel
6.6. By End-users
6.7. By Region

7. Macro Environment and Industry Structure

7.1. Supply Demand Analysis
7.2. Import Export Analysis
7.3. Value Chain Analysis
7.4. PESTEL Analysis
- 7.4.1. Political Factors
- 7.4.2. Economic System
- 7.4.3. Social Implications
- 7.4.4. Technological Advancements
- 7.4.5. Environmental Impacts
- 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
7.5. Porter's Five Forces Analysis
- 7.5.1. Supplier Power
- 7.5.2. Buyer Power
- 7.5.3. Substitution Threat
- 7.5.4. Threat from New Entrant
- 7.5.5. Competitive Rivalry

8. Market Dynamics

8.1. Growth Drivers
8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

9.1. Clinical Trials
9.2. Patent Landscape
9.3. Regulatory Approvals
9.4. Innovations/Emerging Technologies

10. Key Players Landscape

10.1. Competition Matrix of Top Five Market Leaders
10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
10.4. SWOT Analysis (For Five Market Players)
10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

13.1. Novartis AG
- 13.1.1. Company Details
- 13.1.2. Key Management Personnel
- 13.1.3. Products & Services
- 13.1.4. Financials (As reported)
- 13.1.5. Key Market Focus & Geographical Presence
- 13.1.6. Recent Developments
13.2. GSK plc
13.3. EpiVax, Inc.
13.4. Genentech, Inc.
13.5. Amgen Inc.
13.6. Bristol-Myers Squibb Co
13.7. Pfizer Inc.
13.8. AstraZeneca plc
13.9. Eli Lilly And Co
13.10. Boehringer Ingelheim International GmbH
13.11. ImmunityBio, Inc.
13.12. Annexon, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

モノクローナル抗体の世界市場：生産方法別、適応症別、由来別、投与経路別、流通チャネル別、エンドユーザー別、地域別、機会、予測、2017年～2031年

Monoclonal Antibodies Market Assessment, By Production Methods, By Indication, By Source, By Route of Administration, By Distribution Channel, By End-users, By Region, Opportunities and Forecast, 2017-2031F

全表示

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界のモノクローナル抗体市場の見通し、2017年～2031年

第5章 世界のモノクローナル抗体市場の見通し、地域別、2017年～2031年

第6章 市場マッピング、2023年

第7章 マクロ環境と産業構造

第8章 市場力学

第9章 規制の枠組みとイノベーション

第10章 主要参入企業の情勢

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

第14章 戦略的提言

第15章 お問合せと免責事項

List of Tables

List of Figures

Escalating Chronic Disease Prevalence

Technological Advancements

Government Initiatives

Monoclonal Antibodies for Cancer Treatment

Dominance of Chimeric Monoclonal Antibody

Future Market Scenario

Key Players Landscape and Outlook

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Monoclonal Antibodies Market Outlook, 2017-2031F

5. Global Monoclonal Antibodies Market Outlook, By Region, 2017-2031F

6. Market Mapping, 2023

7. Macro Environment and Industry Structure

8. Market Dynamics

9. Regulatory Framework and Innovation

10. Key Players Landscape

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

14. Strategic Recommendations

15. About Us & Disclaimer

第1章調査手法

第2章プロジェクトの範囲と定義

第3章エグゼクティブサマリー

第4章世界のモノクローナル抗体市場の見通し、2017年～2031年

第5章世界のモノクローナル抗体市場の見通し、地域別、2017年～2031年

第6章市場マッピング、2023年

第7章マクロ環境と産業構造

第8章市場力学

第9章規制の枠組みとイノベーション

第10章主要参入企業の情勢

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

第14章戦略的提言

第15章お問合せと免責事項